Author

Aaron S. Enke

Observed names: A. Enke, Aaron Enke

Institution: Clovis Oncology (United States)

Observed institutions: Clovis Oncology (United States), Synta Pharmaceuticals (United States), Takeda Oncology (United States)

OpenAlex ID: A5063384397

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

2020 · Martin H. Voss, Michael S. Gordon, et al. · British Journal of Cancer · 91

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

2018 · Kathleen N. Moore, Todd M. Bauer, et al. · ESMO Open · 45

Abstract CT251: LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors

2022 · Jonathan McConathy, Mallika Dhawan, et al. · Cancer Research · 10

547P Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)

2020 · T.A. Yap, E.P. Hamilton, et al. · Annals of Oncology · 8

Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions

2023 · Sherly Mosessian, Jessica D. Jensen, et al. · PET Clinics · 7

A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies

2016 · D. Juric, J. Lopez, et al. · European Journal of Cancer · 7

The GALAXY Trial(NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC.

2012 · Glenwood D. Goss, Christian Manegold, et al. · Journal of Clinical Oncology · 5

Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

2021 · Ecaterina Elena Dumbrava, Geoffrey Shapiro, et al. · Journal of Clinical Oncology · 4

The Galaxy Trial (NCT01348126): A Randomized IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone as Second Line Therapy in Patients with Stage IIIB or IV NSCLC

2012 · S.S. Ramalingam, B. Zaric, et al. · Annals of Oncology · 3

A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy

2017 · T.K. Choueiri, C. Porta, et al. · Annals of Oncology · 2

Abstract CT124: Evaluation of rucaparib in Japanese patients (pts) with a previously treated advanced solid tumor

2021 · Kenji Tamura, Koji Matsumoto, et al. · Cancer Research · 1

Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

2010 · R. W. Holloway, M. Roche, et al. · Journal of Clinical Oncology · 1

Phase 1 study of investigational oral mTORC1/2 inhibitor TAK-228 (MLN0128): Tolerability and food effects of a milled formulation in patients (pts) with advanced solid tumors

2016 · K.N. Moore, T.M. Bauer, et al. · Annals of Oncology

Works count: 13

Citation count: 184

H-index: 6

I10-index: 3